Perfusion process cell culture method for CHO cell inoculation based on ultra-high density cryopreservation
Through ultra-high density frozen CHO cells, the N-1 cans of seed expansion and optimized perfusion culture is directly carried out, which solves the problems of long seed expansion time and high pollution risk, and achieves efficient and robust cell culture, reducing production costs and manpower. need.
Patent Information
- Application Number
- CN202310607562.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-26
- Publication Date
- 2024-11-26
AI Technical Summary
In the prior art, the seed amplification time of CHO cells and the number of passages is long, resulting in unstable production, high risk of pollution, and requires a lot of manpower and loss of cGMP production facilities.
Ultra-high density frozen CHO cells were used to directly expand N-1 cans, simplifying the cell culture process, shortening the seed amplification time, reducing the number of passages, reducing the risk of contamination, and improving production efficiency by optimizing the perfusion culture conditions.
It significantly shortens cell culture time, improves production efficiency, reduces pollution risks and manpower demand, ensures the robustness of output and quality, and is in line with the concept of lean operation.
Smart Images

Figure CN119020293A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a perfusion process cell culture method based on inoculation of ultra-high density frozen CHO cells, and belongs to the technical field of cell culture. Background Art
[0002] With the remarkable progress in cell engineering, cell culture media and process development in recent years, the expression level of CHO cells has been significantly improved. The in vitro culture of mammalian cells is more difficult than traditional microbial cell culture, mainly because mammalian cells have a long doubling time, complex metabolic pathways, strong sensitivity to the external environment, strict nutritional requirements, and the cell state is easy to change during the culture process. Currently, the commonly used mammalian cell culture processes are: batch culture, fed-batch culture and perfusion culture. Based on the significant advantages of mammalian cell perfusion culture technology in product yield, quality and cost, more and more approved biopharmaceuticals are produced using perfusion culture technology. The development and optimization of perfusion culture technology has become a hot spot in the current research of mammalian cell culture technology.
[0003] Perfusion cell culture is to add cells and culture medium into the reactor together. During the process of cell growth and product formation, part of the conditioned culture medium is continuously removed, and new culture medium is continuously perfused. Most of the cells are retained in the reactor. Cell culture is carried out using a stirred bioreactor and a cell interception flow device (ATF) system. The perfusion culture of cells generally involves thawing the cells, amplifying the seeds to a certain cell density, and then carrying out production culture. For example, in the prior art, relatively low-density frozen cells (15×10 6 After being revived and seeded to a higher density in a shake flask, the cells were transferred to a perfusion tank and expanded to N-1 tanks until the cell density reached 40×10 6 When the concentration of cells / mL is about 100 μg / mL, switch the perfusion medium for perfusion culture.
[0004] Therefore, the current cell culture method has the following problems:
[0005] (1) The seed cell expansion time is relatively long. It takes at least half a month from recovery to expansion to a density sufficient for inoculating the N-1 tank perfusion seed expansion stage.
[0006] (2) The rate of change associated with cell generation is uncontrollable, and the more times the cells are passaged, the less robust the production cells become;
[0007] (3) The open aseptic operation of seed cells at the shake flask scale results in a high risk of contamination;
[0008] (4) Maintaining cells during the seed expansion phase requires a lot of manpower; cGMP production facilities have high losses and manpower.
[0009] Therefore, it is urgent to develop a cell culture method that can shorten the production time while ensuring the output and quality of the product, thereby improving production efficiency and reducing production costs. Summary of the invention
[0010] Problem that the invention aims to solve
[0011] In view of the problems existing in the prior art, the present invention provides a perfusion process cell culture method based on inoculation of ultra-high density frozen CHO cells.
[0012] Solutions for solving problems
[0013] In view of the problems existing in the above-mentioned prior art, the inventors conducted in-depth research and directly expanded the cells in N-1 tanks after thawing the cells frozen at ultra-high density, and then carried out N tank perfusion culture after expansion. This simplified the cell culture process, saved about half a month compared with the traditional cell culture process, improved the process development efficiency under the premise of comparable yield and quality, reduced the risk of contamination in the seed expansion stage, and made the production cells more robust due to the reduction in the number of cell passages, which was more in line with the concept of lean operation.
[0014] The technical solution of the present invention is as follows:
[0015] [1]. A method for culturing CHO cells, comprising the following steps:
[0016] (1) Thawing the frozen ultra-high density CHO cell seeds;
[0017] (2) directly inoculating the thawed CHO cell seeds in step (1) into a bioreactor tank for seed expansion culture;
[0018] (3) performing perfusion culture on the seed cells obtained by the amplification culture in step (2);
[0019] The cell density of the frozen ultra-high density CHO cell seeds is not less than 100×10 6 / mL, preferably not less than 150×10 6 Pieces / mL;
[0020] Preferably, the seed expansion culture is an N-1 tank seed expansion culture;
[0021] Preferably, the tank flow culture is N tank perfusion culture.
[0022] [2] The method for culturing CHO cells according to [1], wherein in step (2), the initial cell density of the CHO cells in the reaction system is not less than 8.0×106 / mL, and the culture medium used includes a seed culture medium, preferably a CD-CHO culture medium, and more preferably a pressurized CD-CHO culture medium.
[0023] [3]. The method for culturing CHO cells according to [2], wherein the specific operation of the seed expansion culture in step (2) comprises: directly inoculating the thawed CHO cell seeds into a tank containing a seed culture medium, carrying out expansion culture at a perfusion rate of 1.0 to 2.5 VVD, controlling the culture temperature at 36.0 to 37.0°C, controlling the dissolved oxygen range at 20% to 80%, controlling the pH value at 6.65 to 7.35, and stirring at a speed of 220 to 400 rpm.
[0024] [4] The method for culturing CHO cells according to any one of [1] to [3], wherein the cell density of the seed expansion culture is not less than 40.0×10 6 When the concentration of 5-6-nitropropene was 400 μg / mL, the tank flow culture medium was switched to perform perfusion culture; preferably, the perfusion culture medium was 73434 culture medium.
[0025] [5]. The method for culturing CHO cells according to any one of [1] to [4], wherein the specific operation of the perfusion culture in step (3) comprises: perfusing the perfusion culture medium at a perfusion rate of 1.0 to 2.5 VVD, controlling the temperature at 36.0 to 37.0°C, controlling the dissolved oxygen range at 20% to 80%, controlling the pH value at 6.65 to 7.35, and stirring at a speed of 220 to 400 rpm.
[0026] [6] The method for culturing CHO cells according to any one of [1] to [5], wherein the cells in step (3) are cultured to a cell density greater than 40.0×10 within 6 days from the start of seed expansion culture. 6 When the concentration reaches 100 μg / mL, cool down to 32-34°C.
[0027] [7] The method for culturing CHO cells according to any one of [1] to [6], wherein during the perfusion culture in step (3), the glucose concentration in the reaction system is controlled to be not less than 2.00 g / L, and when the glucose concentration in the reaction system is lower than 2.00 g / L, glucose is added to maintain the glucose concentration in the reaction system at not less than 2.00 g / L, and when the glucose concentration is higher than 3.00 g / L, the amount of glucose added is gradually reduced until the addition is stopped;
[0028] Optionally, when the glucose concentration is lower than 2.00 g / L, the glucose addition rate is increased in units of 1.00 g / L / day until the concentration is no longer lower than 2.00 g / L;
[0029] Optionally, when the glucose concentration is greater than 3.00 g / L, the glucose feed rate is sequentially reduced in units of 1.00 g / L / day;
[0030] Optionally, the total perfusion culture time is 25±5 days.
[0031] [8] The method for culturing CHO cells according to any one of [1] to [7], wherein the CHO cells are CHO cells encoding exogenous proteins; preferably, the CHO cells are CHO-K1, CHO-S, CHO-K1SV, CHO-GS or CHO-DG44, and the exogenous protein is an antibody; more preferably, the exogenous protein is a monoclonal antibody or a bispecific antibody.
[0032] [9] The method for culturing CHO cells according to any one of [1] to [8], wherein the method for preparing the frozen ultra-high density CHO cell seeds comprises:
[0033] CHO cells were seeded at 0.3-0.7×10 6 The density of cells / mL was inoculated into a shake flask containing seed culture medium for step-by-step amplification culture;
[0034] Then the cells were inoculated into the cell bioreactor and expanded to a cell density of 40×10 6 After that, the cells were perfused and cultured at 1.0-2.5VVD to an ultra-high cell density;
[0035] The cells were directly frozen without concentration or other operations in a 100 mL cryopreservation bag containing 6% to 10% cell cryoprotectant DMSO and pressurized CD CHO culture medium.
[0036] Effects of the Invention
[0037] It can be seen from the technical solution of the present invention that the technical solution of the present invention has the following beneficial effects compared with the prior art:
[0038] (1) The perfusion cell culture method provided by the present invention can save about half a month of seed expansion time for N-1 tank expansion culture of high-density CHO cells, greatly shorten the cell culture time, improve production efficiency, save manpower for maintaining cells during the seed expansion stage, and reduce the loss and manpower of cGMP production facilities;
[0039] (2) The perfusion cell culture method provided by the present invention is to directly expand the high-density CHO cell N-1 tank culture, reduce the number of cell passages and reduce the change rate related to the cell generation, making the production cells more robust;
[0040] (3) The perfusion cell culture method provided by the present invention can provide a higher cell density. The high density and larger volume cell bank in the reactor avoids the open aseptic operation in the shake flask, reducing the risk of contamination. At the same time, the higher cell density can increase the yield and increase the volumetric yield.
[0041] (4) The perfusion cell culture method provided by the present invention can obtain protein products with a yield and quality comparable to that of the traditional seed recovery and amplification followed by the same perfusion culture method. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 A curve chart showing the change of live cell density over time in the experimental group and the control group in the embodiment.
[0043] Figure 2 A curve chart showing the change of cell viability over time in the experimental group and the control group in the embodiment is shown.
[0044] Figure 3 A curve chart showing the changes in glucose metabolism over time in the experimental group and the control group in the example.
[0045] Figure 4 A curve chart showing the changes in lactate metabolism of cells in the experimental group and the control group over time in the example.
[0046] Figure 5 The NH4 of cells in the experimental group and the control group in the embodiment are shown. + Graph of metabolism over time.
[0047] Figure 6 A curve chart showing the change of yield over time in the experimental group and the control group in the embodiment is shown.
[0048] Figure 7 The bar graph shows the cumulative yields from day 8 to day 21 in the experimental group and the control group in the example. DETAILED DESCRIPTION
[0049] Various exemplary embodiments, features and aspects of the present invention will be described in detail below. The word "exemplary" used here means "used as an example, embodiment or illustrative". Any embodiment described here as "exemplary" is not necessarily interpreted as being superior or better than other embodiments.
[0050] In addition, in order to better illustrate the present invention, numerous specific details are provided in the following specific embodiments. It should be understood by those skilled in the art that the present invention can be implemented without certain specific details. In other examples, methods, means, equipment and steps well known to those skilled in the art are not described in detail in order to highlight the subject matter of the present invention.
[0051] definition
[0052] When used in conjunction with the term "comprising" in the claims and / or the specification, the word "a" or "an" can mean "one", but can also mean "one or more", "at least one" and "one or more than one".
[0053] As used in the claims and description, the words "comprising," "having," "including," or "containing" are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
[0054] As used herein, the term "about" means that a value includes the standard deviation of error of the device or method used to determine the value. Exemplarily, the standard deviation is generally within the range of 20-30% of the original value.
[0055] Although the disclosure supports the definition of the term "or" as only alternatives and "and / or", the term "or" in the claims means "and / or" unless it is explicitly stated that it is only alternatives or the alternatives are mutually exclusive. In this specification, when the term "and / or" is used to connect two or more options, it should be understood to mean any one of the options or any two or more of the options.
[0056] When used in the claims or specification, a selected / optional / preferred "numerical range" includes both the numerical endpoints at both ends of the range and all natural numbers covered between the numerical endpoints relative to the aforementioned numerical endpoints.
[0057] In the present invention, the term "CHO cells" refers to Chinese hamster ovary (CHO) cells, which are the most widely used mammalian cell expression system for the production of recombinant pharmaceutical proteins and are also a hot topic in bioprocess and drug development research. The culture process of CHO cells is very robust and can produce a variety of recombinant glycoproteins at high levels on a large scale.
[0058] In the present invention, the term "inoculation density" refers to the initial cell density of an inoculated flask or bioreactor.
[0059] In the present invention, the term "cell culture" refers to a method of simulating the in vivo environment (sterility, suitable temperature, pH and certain nutritional conditions, etc.) in vitro to enable cells to survive, grow, reproduce and maintain their main structures and functions.
[0060] In the present invention, the term "perfusion cell culture" or "perfusion culture" refers to adding cells and culture medium into a reactor together, continuously removing part of the conditioned medium during cell growth and product formation, while continuously perfusing new culture medium, and continuously harvesting products from the culture medium during the culture process.
[0061] In the present invention, the term "fed-batch culture" refers to the continuous or intermittent addition of a specific fed-batch culture medium into the reactor to supplement new nutrients according to the metabolic needs of the cells during the culture process.
[0062] In the present invention, the term "bioreactor" refers to a container for culturing cells, which utilizes the biological functions of enzymes or organisms (such as microorganisms) to perform biochemical reactions in vitro, and is a biological function simulator.
[0063] As used herein, the term "dissolved oxygen" or "DO" refers to the percentage of dissolved oxygen present in a given liquid (such as a cell culture medium) based on saturated air.
[0064] In the present invention, the term "cell bleeding" refers to the removal of a portion of the culture medium from the tank during the perfusion culture process to determine the cell growth rate to maintain a high cell activity and prevent the cell retention module of the perfusion system from being blocked.
[0065] In the present invention, the term "viable cell density" refers to the number of viable cells per unit area or volume, and is used to reflect the cell growth status.
[0066] In the present invention, the term "cell viability" refers to the percentage of live cells in the total cell population.
[0067] In the present invention, the term "cumulative yield" refers to the total yield in one culture cycle.
[0068] In the present invention, the term "perfusion flow rate" is a key parameter for process performance, which is usually defined as the perfusion rate (tank volume per day, VVD, L / (L·day)) or the cell specific perfusion rate (cell specific perfusion rate, CSPR, nL / cell / day).
[0069] In the present invention, the term "VCD (viable cell density)" or "viable cell density" refers to the number of viable cells contained in a certain volume of culture medium, and is expressed in the unit of "cells / mL" or "cells / mL".
[0070] In the present invention, the term "VIB (Viability)" or "cell viability" refers to the ratio of the total number of viable cells contained in a certain volume of culture medium to the total number of cells, and is expressed in the unit "%".
[0071] In the present invention, the term "antibody expression level" refers to the total amount of antibodies produced in a certain volume of cell culture, and is expressed in the unit of "g / L".
[0072] In the present invention, the term "specific productivity" refers to growth rate and productivity calculated in units of picograms of protein produced per cell per day.
[0073] As used herein, the term "aggregate" refers to the association of two or more antibodies or antibody fragments. For example, the aggregate can be a dimer, trimer, tetramer or a multimer greater than a tetramer of an antibody and / or antibody fragment. Antibody aggregates can be soluble or insoluble. The association between aggregated molecules can be covalent or non-covalent, regardless of the mechanism of their association. The association can be a direct association between aggregated molecules, or an indirect association by other molecules that connect them together. Examples of the latter include, but are not limited to, disulfide bonds with other proteins, hydrophobic associations with lipids, charge associations with DNA, affinity associations with leached protein A, or mixed mode associations with multiple components. Aggregates can be irreversibly formed during protein expression in cell culture, during protein purification in downstream processing, or during storage of drug products. The presence of aggregates in solution can be determined using, for example, size exclusion chromatography (SEC) (e.g., SEC with a UV detector, SEC with a light scattering detector (SEC-LSD)), field flow fractionation, analytical ultracentrifugation sedimentation rate techniques, or sodium dodecyl sulfate-capillary electrophoresis (CE-SDS, reduced and non-reduced).
[0074] In the present invention, an alternating tangential flow (ATF) cell retention device with a hollow fiber filter is used to retain cells. In the ATF mode, a diaphragm pump is used to alternately "push-pull" the cell suspension in the fiber column. Because a peristaltic pump is not used, the effect on the cells is small, and the alternating flow forms a backwash on the membrane surface, which is beneficial to reduce the effect of blockage on the filtration efficiency.
[0075] <Method for culturing ultra-high density CHO cells>
[0076] CHO cells were seeded at 0.3-0.7×10 6 The density of cells / mL was inoculated into a shake flask containing seed culture medium for step-by-step amplification culture;
[0077] Then the cells were inoculated into the cell bioreactor and expanded to a cell density of 40×10 6After that, the cells were perfused and cultured at 1.0-2.5VVD to an ultra-high cell density;
[0078] Furthermore, the cells are directly frozen without concentration or other operations in a 100 mL cryopreservation bag containing 6% to 10% cell freeze-drying protective agent DMSO and seed culture medium (preferably pressurized CD CHO culture medium) so that the frozen cell density is not less than 150×10 6 / mL. Optionally, the lyophilization protective agent includes trehalose, polyvinylpyrrolidone (PVP), levotrans, dimethyl sulfoxide, etc., preferably dimethyl sulfoxide. Optionally, the seed culture medium includes CD-CHO culture medium, preferably pressurized CD-CHO culture medium.
[0079] (CHO cells)
[0080] In some embodiments, the CHO cell is a CHO cell containing an encoded exogenous protein; preferably, the CHO cell is CHO-K1, CHO-S, CHO-K1SV, CHO-GS or CHO-DG44, and the exogenous protein is an antibody; more preferably, the exogenous protein is a monoclonal antibody or a bispecific antibody.
[0081] In some specific embodiments, the CHO cell is CHO-K1, and the exogenous protein is a bispecific antibody.
[0082] In some preferred embodiments, the bispecific antibody sequence is disclosed in the patent with international publication number WO2020151762A1. The antibody sequence is obtained in Example 1. The gene sequence encoding the antibody is constructed in CHO-K1 cells according to conventional biological methods, and the obtained CHO-K1 cells are screened by well plates to establish a monoclonal antibody primary cell library (PCB).
[0083] [Seed expansion culture]
[0084] In some embodiments, the seed expansion culture is an N-1 pot seed expansion culture.
[0085] In some specific embodiments, the seed expansion culture operation in step (2) is:
[0086] The cell cryopreservation bag was thawed in a 36.5-37.5°C water bath, and the thawed CHO cells were inoculated into a bioreactor (tank) with a certain volume of seed culture medium to start N-1 tank expansion culture, and the expansion culture was carried out at a perfusion rate of 1.0-2.5VVD. The culture temperature was controlled at 36.0-37.0°C, the dissolved oxygen range was controlled at 20%-80%, the pH value was controlled at 6.65-7.35, and the stirring speed was 220-400rpm. Optionally, the culture temperature is controlled at 36.0° C., 36.5° C., 37.0° C., the dissolved oxygen range is controlled at 20%, 30%, 40%, 50%, 60%, 70% or 80%, and the pH value is controlled at 6.65, 6.70, 6.75, 6.80, 6.85, 6.90, 6.95, 7.00, 7.05, 7.10, 7.15, 7.20, 7.25, 7.30 or 7.35. The process parameters including perfusion rate, culture temperature, dissolved oxygen range, pH value and stirring speed are adjusted according to the cell type and cell growth status.
[0087] In some specific embodiments, the seed culture medium is CD-CHO medium, preferably pressurized CD-CHO medium.
[0088] When the seed amplification culture reaches a cell density of not less than 40.0×10 6 When the number of cells / mL was reached, the medium was switched to perfusion culture.
[0089] [Perfusion culture]
[0090] In some preferred embodiments, the tank flow culture is N tank perfusion culture.
[0091] In some specific embodiments, the perfusion culture in step (3) is performed by perfusing the perfusion medium at a perfusion rate of 1.0 to 2.5 VVD, controlling the temperature at 36.0 to 37.0° C., the dissolved oxygen range at 20% to 80%, the pH value at 6.65 to 7.35, and the stirring speed at 220 to 400 rpm. The process parameters including the perfusion rate, culture temperature, dissolved oxygen range, pH value, and stirring speed are adjusted according to the cell type and cell growth state.
[0092] Furthermore, when the perfusion culture reached a cell density greater than 40.0×10 6 When the concentration reaches 100 μg / mL, cool down to 32-34°C.
[0093] In some specific embodiments, the cells are cultured to a cell density greater than 40.0×10 within 6 days from the start of seed expansion culture. 6 More specifically, the temperature is lowered to 32-34°C, preferably 33°C, on the day after switching the perfusion medium.
[0094] Optionally, the total perfusion culture time is 25±5 days.
[0095] (Perfusion medium)
[0096] In some embodiments, the perfusion medium used in the perfusion culture process is a medium suitable for animal cells, such as mammalian cells, to grow in vitro cell culture, especially CHO cells. Typically, the perfusion medium is composed of a buffer, salts, carbohydrates, amino acids, vitamins and trace elements, and can be selected from CD-CHO medium, Hycell CHO medium or 73434 medium.
[0097] In some preferred embodiments, the perfusion medium is 73434 medium.
[0098] (Glucose concentration and glucose addition)
[0099] During the perfusion culture process, when the detected glucose concentration in the reaction system is lower than 2.00 g / L, glucose is added to maintain the glucose concentration in the reaction system not lower than 2.00 g / L. When the detected glucose concentration is higher than 3.00 g / L, the amount of glucose added is gradually reduced until the addition is stopped.
[0100] In some optional embodiments, when the detected glucose concentration is lower than 2.00 g / L, the flow rate of glucose is increased in units of 1.00 g / L / day until the detected glucose concentration is no longer lower than 2.00 g / L; when the detected glucose concentration is greater than 3.00 g / L, the flow rate of glucose is decreased in units of 1.00 g / L / day.
[0101] Exemplarily, the glucose addition rate is increased in units of 1.00 g / L / day, which means that 1 g / L (based on the volume of the reaction system) of glucose is added within 24 hours. If the detected concentration of glucose in the reaction system is still lower than 2.00 g / L after the addition of 1 g / L of glucose, the glucose addition rate within 24 hours is increased. For example, 2 g / L (based on the volume of the reaction system) of glucose is added within 24 hours. According to this step, the detected concentration of glucose in the reaction system is maintained at not less than 2.00 g / L and not more than 3.00 g / L.
[0102] Exemplarily, the amount of glucose added is reduced in units of 1.00 g / L / day, which means that the amount of glucose added every 24 hours is reduced by 1 g / L on the basis of the original amount of glucose added. If the detected concentration of glucose in the reaction system is still greater than 3.00 g / L, the amount of glucose added every 24 hours is further reduced by 1 g / L. According to this step, the detected concentration of glucose in the reaction system is maintained at not less than 2.00 g / L and not greater than 3.00 g / L.
[0103] Example
[0104] The embodiments of the present invention will be described in detail below in conjunction with the examples, but those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be considered to limit the scope of the present invention. If no specific conditions are specified in the examples, they are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be obtained commercially.
[0105] 1. Key instruments and equipment
[0106]
[0107] 2. Key reagent information
[0108]
[0109] The pressurized CD-CHO medium used in the following examples is a CD-CHO medium containing 0.1% (v / v) 50 mM MSX.
[0110] Example 1: Cell line construction
[0111] The cells used in the experiment were CHO-K1 cells (batch number: 20170227-Lonza-GS-CHO, P6), which were purchased from LONZA. The coding gene sequence of the antibody (the sequence has been disclosed in the antibody sequence obtained in Example 1 of the patent with international publication number WO2020151762A1, which is incorporated into the present invention by reference) was constructed in CHO-K1 cells according to conventional biological methods, and a monoclonal antibody original cell library (PCB) was established after well plate screening.
[0112] Example 2: Cell seed source and perfusion culture process
[0113] The yield and quality of the two different frozen cells cultured by the same density inoculation perfusion process were compared. The experimental cells and the control group cells were derived from the PCB constructed in Example 1, the experimental group sample name: IBI323-20230320B-252 (corresponding to the experimental group cell number: IBI323-2-34-028-P7D4-RM-D7), and the control group sample name: IBI323-20230320B-251 (corresponding to the control group cell number: IBI323-2-34-028-P6).
[0114] Experimental Group:
[0115] (1) The experimental group cells were seeded at 0.3-0.7×10 6The cells were inoculated into a 250 mL shake flask containing CD-CHO at a density of 10 / mL and placed in a carbon dioxide shaker. The culture conditions were: 36.0-37.0°C, 5.0%-7.0% CO2, 120-140 r / min. After culturing for 2-4 days, they were inoculated into a 500 mL shake flask. The cells were cultured for 2-4 days according to the above method. Then, the cells were cultured in 1000 mL and 2000 mL shake flasks in turn according to the above method. After the step-by-step culture, the seed cells were inoculated into a cell bioreactor and continued to expand until the cell density reached 40×10 6 After that, the cells were perfused at 1.0-2.5 VVD until the cell density reached a super high density (no less than 200×10 6 Cells / mL) were directly frozen without concentration in a 100 mL cryopreservation bag containing 6% to 10% cell cryopreservation protectant DMSO and pressurized CD CHO culture medium (no less than 150×10 6 / mL) to obtain a high-density cell seed freezing bag.
[0116] (2) After the high-density cell seed cryopreservation bag was thawed in a 36.5-37.5°C water bath, the DMSO was directly inoculated into a 2L bioreactor tank containing CD-CHO medium with a working volume of 1.0-1.5L perfusion process cell culture without removing DMSO, and N-1 tank expansion was started; the initial inoculation cell density was not less than 8.0×10 6 / mL, expand the culture at a perfusion rate of 1.0-2.5VVD, control the culture temperature at 36.0-37.0℃, the dissolved oxygen range at 20%-80%, the pH value at 6.65-7.35, and the stirring speed at 220-400rpm. Adjust the air flux at about 10ml / min. After the oxygen is fully vented, the air can be closed. Add defoamer in a timely manner according to the foam situation in the tank to ensure that the foam will not flow out from the tail gas connection port to the tail gas bottle. Take samples every day to test the density, viability and metabolic related parameters. When the seed expansion culture reaches a cell density of not less than 40.0×10 6 / mL and no later than the 6th day after inoculation, switch to tank flow medium for perfusion culture.
[0117] (3) The specific steps of N tank perfusion culture are as follows: switch the culture medium to perfusion culture medium 73434, and perform perfusion culture at 1.0-2.5VVD. The temperature is lowered to 33°C the next day after switching the perfusion culture medium. During the perfusion culture stage using perfusion culture medium 73434, the culture temperature after cooling is set to 33.0°C; the dissolved oxygen range is 20%-80%; the acceptable pH range is 6.65-7.35; the stirring speed is 220-400rpm, and it is adjusted in time according to the dissolved oxygen and mixing requirements. The air flux is about 10ml / min, and the air can be closed after the oxygen is long-circulated. Add defoaming agent in a timely and appropriate amount according to the foam situation in the tank to ensure that the foam will not flow out from the exhaust connection port to the exhaust bottle. The culture time is 25±5 days. Glucose is added according to the daily test results of glucose concentration. When the glucose concentration is lower than 2.00g / L, the flow addition is started at a rate of 1.00g / L / day. During the glucose addition process, when the glucose concentration was lower than 2.00 g / L, it was increased in units of 1.00 g / L / day until the concentration was no longer lower than 2.00 g / L; when the glucose concentration was higher than 3.00 g / L, it was decreased in units of 1.00 g / L / day until the glucose addition was stopped.
[0118] Control group:
[0119] (1) The number of cells is not less than 15×10 6 The seed cells were frozen at a density of 100 / mL in fresh seed culture medium (pressurized CD-CHO culture medium) containing 10% (v / v) DMSO. The seed cells were thawed in a 36.5-37.5°C water bath and transferred to a centrifuge tube containing 9 mL seed culture medium. After centrifugation, the supernatant was discarded (the purpose of this step is to wash away DMSO). 30 mL of seed culture medium (pressurized CD-CHO culture medium) was drawn into a shake flask, 5 mL of which was used to resuspend the seed cells and then transferred to a shake flask for shake flask-scale recovery.
[0120] (2) Take 1-1.5 mL of cell fluid and count it in a cell counting cup. Culture at 36.0-37.0°C, not less than 100 rpm, 3.0-8.0% CO2 for 3-4 days. Take the same volume of cell fluid and count it. When the cell density reaches 2-8×10 6 / mL, when the cell viability is not less than 80%, take a certain volume of cell solution for passage / expansion to a new shake flask, and add a sufficient amount of seed culture medium (pressurized CD-CHO culture medium). Repeat the passage / expansion operation until the seed cell solution reaches a sufficient amount of cells for inoculation, then inoculate it into a 2L bioreactor, and add fresh seed culture medium until the cell density is not less than 8.0×10 6 / mL began to expand the N-1 tank and perfuse the N tank (the process parameters were the same as the experimental group), and the inoculation density was consistent with the experimental group.
[0121] During the culture process, a certain amount of culture medium was taken every day to measure the viable cell density, cell viability, glucose concentration, lactic acid concentration, NH4 + Ion concentration; the inoculation day is day 0 (D0), and from day 8 (D8), the ATF end liquid is collected and 0.5 mL of sample is taken to detect the daily antibody production on the Cedex biochemical detector, and the cumulative production from day 8 to day 21 is calculated. From the day of switching the perfusion culture medium, 30 to 50 mL is reserved every five days for purification, and the purified samples are tested for sample quality using molecular exclusion high performance liquid chromatography (SEC-HPLC), non-reducing CE-SDS (nrCE-SDS), and iCIEF-HPLC.
[0122] The cumulative production is the sum of the daily production (mg / L) from day 8 to day 21, the perfusion rate, and the initial volume. In this embodiment, the initial volume is 1.3L.
[0123] result:
[0124] (1) Cell growth and metabolism
[0125] As shown in Table 1 and Figure 1 to Figure 7 As shown: The cell growth data showed that the viable cell density (VCD) and peak viable cell density (PK VCD) of the ultra-high density cryopreserved cell group in the first 10 days were slightly lower than those of the traditional low-density cryopreserved cell group, but the viable cell density (VCD) in the later stage of culture (after 10 days) was higher than that of the traditional low-density cryopreserved cell group ( Figure 1 ); and after the 8th day of culture, the cell viability was relatively high ( Figure 2 ); Glucose and lactate metabolism data showed normal and consistent trends with the control group ( Figure 3 and Figure 4 ); Compared with the control group, the experimental group had NH4 + The experimental group had a lower level than the control group, indicating that the cell culture microenvironment in the experimental group was relatively good ( Figure 5 During the 8th to 12th day of cultivation, the yield of the experimental group showed an upward trend, while that of the control group showed a downward trend. After the 14th day, the yields of the two groups were consistent ( Figure 6 ). Regarding the cumulative yield, the experimental group and the control group reached the same level. From the 8th to the 21st day after inoculation, the cumulative total yield of 14 days of perfusion was 31.5g and 31.8g respectively.
[0126] Table 1. Daily production and perfusion rate in the experimental group and the control group from day 8 to day 21
[0127]
[0128] Note: Perfusion rate (tank volume per day, VVD, L / (L·day)).
[0129] (2) Product quality
[0130] The quality data are shown in Table 2. From the quality data of the control group IBI323-20230320B-251-D13 and the experimental group IBI323-20230320B-252-D14, which were retained on the 10th day after the perfusion medium was switched (the experimental group and the control group were the 4th and 3rd days after inoculation, respectively), the content of aggregates (HMW) detected by the SEC method was consistent with the main peak height; the content of fragments detected by the nrCE method was similar; and the glycosylation type and ratio were also comparable. From the quality data of the control group IBI323-20230320B-251-D18 and the experimental group IBI323-20230320B-252-D19, which were retained on the 15th day after the perfusion medium was switched (the experimental group and the control group were the 4th and 3rd days after inoculation, respectively), the content of aggregates (HMW) detected by the SEC method was consistent with the main peak height; the content of fragments detected by the nrCE method was similar; and the glycosylation type and ratio were also comparable. In summary, the quality of the experimental group and the control group is comparable.
[0131] Table 2. Quality comparison between experimental group and control group
[0132]
[0133] It should be noted that, although the technical solution of the present invention is introduced with specific examples, those skilled in the art will appreciate that the present invention should not be limited thereto.
[0134] The embodiments of the present invention have been described above, and the above description is exemplary, not exhaustive, and is not limited to the disclosed embodiments. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments. The selection of terms used herein is intended to best explain the principles of the embodiments, practical applications, or technical improvements in the market, or to enable other persons of ordinary skill in the art to understand the embodiments disclosed herein.
Claims
1. A method for culturing CHO cells, It is characterized in that The steps include: (1) Thawing the frozen ultra-high density CHO cell seeds; (2) directly inoculating the thawed CHO cell seeds in step (1) into a bioreactor tank for seed expansion culture; (3) performing perfusion culture on the seed cells obtained by the amplification culture in step (2); The cell density of the frozen ultra-high density CHO cell seeds is not less than 100×10 6 / mL, preferably not less than 150×10 6 Pieces / mL; Preferably, the seed expansion culture is an N-1 tank seed expansion culture; Preferably, the tank flow culture is N tank perfusion culture.
2. The method for culturing CHO cells according to claim 1, It is characterized in that In step (2), the initial cell density of CHO cells inoculated in the reaction system is not less than 8.0×10 6 / mL, and the culture medium used includes a seed culture medium, preferably a CD-CHO culture medium, and more preferably a pressurized CD-CHO culture medium.
3. The method for culturing CHO cells according to claim 2, It is characterized in that The specific operation of the seed expansion culture in step (2) includes: directly inoculating the thawed CHO cell seeds into a bioreactor tank containing a seed culture medium, performing expansion culture at a perfusion rate of 1.0 to 2.5 VVD, controlling the culture temperature at 36.0 to 37.0°C, controlling the dissolved oxygen range at 20% to 80%, controlling the pH value at 6.65 to 7.35, and stirring at a speed of 220 to 400 rpm.
4. The method for culturing CHO cells according to any one of claims 1 to 3, It is characterized in that When the seed amplification culture reaches a cell density of not less than 40.0×10 6 When the concentration of 5-6-nitropropene was 400 μg / mL, the tank flow culture medium was switched to perform perfusion culture; preferably, the perfusion culture medium was 73434 culture medium.
5. The method for culturing CHO cells according to any one of claims 1 to 4, It is characterized in that The specific operation of the perfusion culture in step (3) includes: perfusing the perfusion culture medium at a perfusion rate of 1.0 to 2.5 VVD, controlling the temperature at 36.0 to 37.0°C, controlling the dissolved oxygen range at 20% to 80%, controlling the pH value at 6.65 to 7.35, and stirring at a speed of 220 to 400 rpm.
6. The method for culturing CHO cells according to any one of claims 1 to 5, It is characterized in that When the cells in step (3) are cultured to a cell density greater than 40.0×10 within 6 days from the start of seed expansion culture, 6 When the concentration reaches 100 μg / mL, cool down to 32-34°C.
7. The method for culturing CHO cells according to any one of claims 1 to 6, It is characterized in that During the perfusion culture of step (3), the concentration of glucose in the reaction system is controlled to be not less than 2.00 g / L. When the concentration of glucose in the reaction system is lower than 2.00 g / L, glucose is added to maintain the concentration of glucose in the reaction system to be not less than 2.00 g / L. When the concentration of glucose is higher than 3.00 g / L, the amount of glucose added is gradually reduced until the addition is stopped. Optionally, when the glucose concentration is lower than 2.00 g / L, the glucose addition rate is increased in units of 1.00 g / L / day until the concentration is no longer lower than 2.00 g / L; Optionally, when the glucose concentration is greater than 3.00 g / L, the glucose feed rate is sequentially reduced in units of 1.00 g / L / day; Optionally, the total perfusion culture time is 25±5 days.
8. The method for culturing CHO cells according to any one of claims 1 to 7, It is characterized in that The CHO cell is a CHO cell containing a protein encoding an exogenous protein; preferably, the CHO cell is CHO-K1, CHO-S, CHO-K1SV, CHO-GS or CHO-DG44, and the exogenous protein is an antibody; more preferably, the exogenous protein is a monoclonal antibody or a bispecific antibody.
9. The method for culturing CHO cells according to any one of claims 1 to 8, It is characterized in that The method for preparing the frozen ultra-high density CHO cell seeds comprises: CHO cells were seeded at 0.3-0.7×10 6 The density of cells / mL was inoculated into a shake flask containing seed culture medium for step-by-step amplification culture; Then the cells were inoculated into the cell bioreactor and expanded to a cell density of 40×10 6 After that, the cells were perfused and cultured at 1.0-2.5VVD to an ultra-high cell density; The cells were directly frozen without concentration or other operations in a 100 mL cryopreservation bag containing 6% to 10% cell cryoprotectant DMSO and pressurized CD CHO culture medium.
Citation Information
Cited By
Production method of Oumoprayer's monoclonal antibody stock solution and Oumoprayer's monoclonal antibody stock solution
CN119524125A
